Showing results (1091-1100 of 1,984) with videos related to
Sort By:
Pageof 199
The Lancet. Neurology|January 21, 2020
The characterisation of subjective cognitive declineFrank Jessen, Rebecca E Amariglio, Rachel F Buckley, et al.The Lancet. Neurology|November 19, 2020
Sleep disorders in autoimmune encephalitisAmaia Muñoz-Lopetegi, Francesc Graus, Josep Dalmau, et al.The Lancet. Neurology|November 19, 2020
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Michael Polydefkis, Alejandra González-Duarte, et al.The Lancet. Neurology|October 25, 2020
Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trialStephen R Rapp, Sarah A Gaussoin, Bonnie C Sachs, et al.The Lancet. Neurology|October 25, 2020
Monogenic variants in dystonia: an exome-wide sequencing studyMichael Zech, Robert Jech, Sylvia Boesch, et al.The Lancet. Neurology|October 25, 2020
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementiasGaël Chételat, Javier Arbizu, Henryk Barthel, et al.The Lancet. Neurology|September 19, 2020
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trialWim M Mulleners, Byung-Kun Kim, Miguel J A Láinez, et al.The Lancet. Neurology|September 19, 2020
Potential human transmission of amyloid β pathology: surveillance and risksElsa Lauwers, Giovanna Lalli, Sebastian Brandner, et al.The Lancet. Neurology|January 26, 2020
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trialJeremy Chataway, Floriana De Angelis, Peter Connick, et al.The Lancet. Neurology|January 22, 2019
Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapiesDavid R Beers, Stanley H AppelPageof 199